Nussbaum Ran
SEC-identified person · CIK 1609805 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| LB Pharmaceuticals INC LBRX | Director | filed 2025 - 2026 |
| Keros Therapeutics, Inc. KROS | Director | filed 2020 - 2025 |
| Urogen Pharma Ltd. URGN | Director | filed 2019 - 2023 |
| Sevion Therapeutics, Inc. SVOND | Director | filed 2017 - 2022 |
| Prevail Therapeutics Inc. PRVL | Director | filed 2019 - 2021 |
| Arqule INC arql | Director | filed 2017 - 2020 |
| VBI Vaccines Inc/BC VBIV | Director | filed 2017 - 2017 |
| Kite Pharma, Inc. KITE | Director | filed 2014 - 2017 |
| Laurier International INC LRRI.OB | Officer | filed 2016 - 2016 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.